Latest & greatest articles for atorvastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atorvastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atorvastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atorvastatin

61. A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets

A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets Lachaine J, Merikle E, Tarride J E, Montpetit M, Rinfret S Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the cost-effectiveness of two cholesterol-lowering pharmaceuticals, atorvastatin (10 to 80 mg/day) and generic simvastatin (10 to 80 mg/day). Statin medications treat

NHS Economic Evaluation Database.2007

62. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin

Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin Lindgren P, Graff J, Olsson A G, Pedersen T J, Jonsson B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the long-term cost-effectiveness of two options for the secondary prevention of cardiovascular disease in patients, under 80 years old, who had experienced acute myocardial infarction. At a willingness-to-pay of 50,000 Euros per quality-adjusted life-year, atorvastatin was cost-effective compared with simvastatin in Denmark, Norway and Sweden, while in Finland

NHS Economic Evaluation Database.2007

63. Amlodipine besylate/ atorvastatin calcium

Amlodipine besylate/ atorvastatin calcium Common Drug Review CEDAC Meeting – April 19, 2006 Page 1 of 1 Notice of CEDAC Final Recommendation – May 17, 2006 CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM (Caduet ™ – Pfizer Canada Inc.) Description: Caduet ™ is a fixed dose combination of amlodipine and atorvastatin and is approved for use in patients for whom treatment with both amlodipine and atorvastatin is appropriate, specifically (...) , patients at cardiovascular risk. Dosage Forms: Tablets containing amlodipine/atorvastatin in the following combinations: 5/10 mg, 5/20 mg, 5/40 mg, 5/80 mg, 10/10 mg, 10/20 mg, 10/40 mg and 10/80 mg. Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that Caduet ™ be listed for patients who have been titrated to a stable combination of the separate components, amlodipine and atorvastatin. Reasons for the Recommendation: 1. There were no randomized controlled trials (RCTs

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2006

64. Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus

Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main (...) menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus Article Text Therapeutics Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus Free Apoor S Gami , MD , Steven A Smith , MD Statistics from Altmetric.com No Altmetric data available for this article. Colhoun HM

Evidence-Based Medicine (Requires free registration)2006

65. Are statins created equal: evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention

Are statins created equal: evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention Are statins created equal: evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention Are statins created equal: evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention Zhou Z, Rahme E, Pilote L CRD summary This review assessed (...) the relative efficacy of pravastatin, simvastatin and atorvastatin. The authors concluded that the evidence suggests there is no statistically significant difference in long-term cardiovascular outcomes between standard doses of these statins. Statements on relative efficacy were based on indirect comparisons, thus the authors' cautious conclusion appears appropriate. Authors' objectives To assess the relative efficacy of pravastatin, simvastatin and atorvastatin. Searching MEDLINE and the Cochrane

DARE.2006

66. Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK

Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Davies A, Hutton J, O'Donnell J, Kingslake S Record Status This is a critical abstract (...) rosuvastatin (ROS), atorvastatin (ATO), simvastatin (SIM), pravastatin (PRA) and fluvastatin (FLU). Initial doses were 10 mg for ROS, ATO and SIM, 20 mg for PRA, and 40 mg for FLU. Patients who failed to reach the target cholesterol level with the initial dosage where titrated to the next highest dosage (20 and 40 mg for ROS and PRA, 20, 40 and 80 mg for ATO and SIM, and 40 and 80 mg for FLU). Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study

NHS Economic Evaluation Database.2006

67. Evaluation of the effects of statins (with particular consideration of atorvastatin)

Evaluation of the effects of statins (with particular consideration of atorvastatin) Evaluation of the effects of statins (with particular consideration of atorvastatin) Evaluation of the effects of statins (with particular consideration of atorvastatin) Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Evaluation of the effects of statins (with particular consideration of atorvastatin) Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). 2006 Authors' objectives The aim of this systematic literature review is to describe and evaluate the current evidence available on the therapeutic effects of statins, focussing on the aspects described above

Health Technology Assessment (HTA) Database.2006

68. High-dose atorvastatin after stroke or transient ischemic attack.

High-dose atorvastatin after stroke or transient ischemic attack. 16899775 2006 08 10 2006 08 16 2015 11 19 1533-4406 355 6 2006 Aug 10 The New England journal of medicine N. Engl. J. Med. High-dose atorvastatin after stroke or transient ischemic attack. 549-59 Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they reduce the risk of stroke after a recent stroke or transient ischemic attack (TIA) remains to be established. We randomly (...) assigned 4731 patients who had had a stroke or TIA within one to six months before study entry, had low-density lipoprotein (LDL) cholesterol levels of 100 to 190 mg per deciliter (2.6 to 4.9 mmol per liter), and had no known coronary heart disease to double-blind treatment with 80 mg of atorvastatin per day or placebo. The primary end point was a first nonfatal or fatal stroke. The mean LDL cholesterol level during the trial was 73 mg per deciliter (1.9 mmol per liter) among patients receiving

NEJM2006

69. High dose atorvastatin was superior to standard dose pravastatin in reducing death or major CV events in acute coronary syndrome

High dose atorvastatin was superior to standard dose pravastatin in reducing death or major CV events in acute coronary syndrome High dose atorvastatin was superior to standard dose pravastatin in reducing death or major CV events in acute coronary syndrome | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here High dose atorvastatin was superior to standard dose pravastatin in reducing death or major CV events in acute coronary syndrome Article Text Therapeutics High dose atorvastatin was superior to standard dose pravastatin in reducing death or major

Evidence-Based Medicine (Requires free registration)2005

70. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial

Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin (...) , pravastatin and simvastatin: analysis of the STELLAR trial Hirsch M, O'Donnell J C, Jones P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of rosuvastatin (10 - 40 mg/day), atorvastatin (10 - 80 mg/day), pravastatin (10 - 40 mg

NHS Economic Evaluation Database.2005

71. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial)

Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial) Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial) Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared (...) with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial) Miller P S, Smith D G, Jones P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use rosuvastatin (10, 20 or 40 mg) in the treatment of patients

NHS Economic Evaluation Database.2005

73. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. 16034009 2005 07 21 2005 07 26 2015 11 19 1533-4406 353 3 2005 Jul 21 The New England journal of medicine N. Engl. J. Med. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. 238-48 Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit of statins in such patients receiving hemodialysis, who are at high risk for cardiovascular (...) disease and death, has not been examined. We conducted a multicenter, randomized, double-blind, prospective study of 1255 subjects with type 2 diabetes mellitus receiving maintenance hemodialysis who were randomly assigned to receive 20 mg of atorvastatin per day or matching placebo. The primary end point was a composite of death from cardiac causes, nonfatal myocardial infarction, and stroke. Secondary end points included death from all causes and all cardiac and cerebrovascular events combined

NEJM2005

74. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

Intensive lipid lowering with atorvastatin in patients with stable coronary disease. 15755765 2005 04 07 2005 04 12 2015 11 19 1533-4406 352 14 2005 Apr 07 The New England journal of medicine N. Engl. J. Med. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. 1425-35 Previous trials have demonstrated that lowering low-density lipoprotein (LDL) cholesterol levels below currently recommended levels is beneficial in patients with acute coronary syndromes. We (...) prospectively assessed the efficacy and safety of lowering LDL cholesterol levels below 100 mg per deciliter (2.6 mmol per liter) in patients with stable coronary heart disease (CHD). A total of 10,001 patients with clinically evident CHD and LDL cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) were randomly assigned to double-blind therapy and received either 10 mg or 80 mg of atorvastatin per day. Patients were followed for a median of 4.9 years. The primary end point

NEJM2005

75. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. 16287954 2005 11 18 2005 11 22 2016 10 17 1538-3598 294 19 2005 Nov 16 JAMA JAMA High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. 2437-45 Evidence suggests that more intensive lowering of low-density lipoprotein cholesterol (LDL-C) than (...) enrolled 8888 patients aged 80 years or younger with a history of acute MI. Patients were randomly assigned to receive a high dose of atorvastatin (80 mg/d; n = 4439), or usual-dose simvastatin (20 mg/d; n = 4449). Occurrence of a major coronary event, defined as coronary death, confirmed nonfatal acute MI, or cardiac arrest with resuscitation. During treatment, mean LDL-C levels were 104 (SE, 0.3) mg/dL in the simvastatin group and 81 (SE, 0.3) mg/dL in the atorvastatin group. A major coronary event

JAMA2005

76. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. 15325833 2004 08 24 2004 09 02 2015 11 19 1474-547X 364 9435 2004 Aug 21-27 Lancet (London, England) Lancet Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. 685-96 (...) Type 2 diabetes is associated with a substantially increased risk of cardiovascular disease, but the role of lipid-lowering therapy with statins for the primary prevention of cardiovascular disease in diabetes is inadequately defined. We aimed to assess the effectiveness of atorvastatin 10 mg daily for primary prevention of major cardiovascular events in patients with type 2 diabetes without high concentrations of LDL-cholesterol. 2838 patients aged 40-75 years in 132 centres in the UK and Ireland were

Lancet2004

77. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. 15207950 2004 06 21 2004 07 13 2015 11 19 1474-547X 363 9426 2004 Jun 19 Lancet (London, England) Lancet Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. 2015-21 Rheumatoid arthritis is characterised by inflammatory synovitis, articular destruction, and accelerated atherogenesis. HMG-CoA (3-hydroxy-3-methylglutarylcoenzyme A) reductase (...) inhibitors (statins) mediate clinically significant vascular risk reduction in patients without inflammatory disease and might have immunomodulatory function. We postulated that statins might reduce inflammatory factors in rheumatoid arthritis and modify surrogates for vascular risk. 116 patients with rheumatoid arthritis were randomised in a double-blind placebo-controlled trial to receive 40 mg atorvastatin or placebo as an adjunct to existing disease-modifying antirheumatic drug therapy. Patients were

Lancet2004

78. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus: a subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study

Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus: a subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus: a subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study Early benefit from structured care with atorvastatin in patients (...) with coronary heart disease and diabetes mellitus: a subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study Athyros V G, Papageorgiou A A, Symeonidis A N, Didangelos T P, Pehlivanidis A N, Bouloukos V I, Mikhailidis D P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

NHS Economic Evaluation Database.2003

79. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes

Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes Schwartz G G, Ganz P, Waters D, Arikian S Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of atorvastatin (80 mg/day), initiated 24 to 96 hours after an acute coronary syndrome (ACS), to prevent death and nonfatal ischaemic events in patients with unstable angina or non-Q wave acute myocardial infarction (MI). Type of intervention Secondary prevention. Economic

NHS Economic Evaluation Database.2003

80. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS)

An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS) An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS) An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS) Smith D G, McBurney C R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of atorvastatin (ATO; 10 - 80 mg/day), fluvastatin (FLU; 20 - 40 mg/day or 40 mg twice daily), lovastatin (LOV; 20 - 40 mg/day or 40 mg twice daily), pravastatin (PRA; 10 - 40 mg/day) and simvastatin (SIM; 10 - 40 mg/day) for the treatment of hypercholesterolaemia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study

NHS Economic Evaluation Database.2003